Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 25, 2014

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2038

Conditions
NeuroblastomaGanglioneuroblastoma
Interventions
BIOLOGICAL

Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)

Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)

BIOLOGICAL

Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)

Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt

BIOLOGICAL

Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)

Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (long spacer 2nd generation T cells)

Trial Locations (1)

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
collaborator

The Evan Foundation

OTHER

collaborator

Ben Towne Center for Childhood Cancer Research

OTHER

lead

Seattle Children's Hospital

OTHER